Background {#Sec1}
==========

Presently, numerous types of "omics" data are generated by many accurate and cost-effective methods. For instance, next-generation sequencing (NGS) technology is used to find DNA or RNA variations, bisulfite sequencing is used to find DNA-methylated variants, and multiple reaction monitoring (MRM) is applied to measure protein abundances \[[@CR1]--[@CR3]\]. These efficient omics data platforms allow researchers to use multi-omics data, obtained from the same subjects, for analyzing huge numbers of variants. As a result, efficient multi-omics data analysis is becoming more important in integrating large-scale data sets, making it possible to interpret fundamental biological systems \[[@CR4]\].

MicroRNAs (miRNAs) are noncoding RNAs having a length less than 25 base pairs, regulating the expression of specific genes by mRNA degradation or blocking translation by binding to the 3′ regions of their "target" mRNAs. Many recent studies have now implicated miRNAs in the pathogenesis of cancer, including triggering cancer initiation and progression. MiRNAs have been shown to have tissue-specific and disease-specific expression patterns \[[@CR5]--[@CR8]\]. Intensive investigation is now underway for using applying miRNAs' inhibitory information to mRNAs. For example, Nam et al. developed "miRNA and mRNA integrated analysis" (MMIA) to examine biological functions of miRNA expression \[[9](#Equ9){ref-type=""}\]. Moreover, Buffa et al. used pathway information to independently validate miRNAs significant for breast cancer \[[@CR10]\], while Cho et al. performed network analysis, and hierarchical clustering, to find biological "signatures" of interstitial lung diseases \[[@CR11]\]. Most miRNA and mRNA integration analyses focus on first identifying miRNAs significantly associated with the phenotype of interest, and then experimentally validating those miRNAs' phenotype involvement by inhibiting or ectopically overregulating their expression \[[@CR9]--[@CR11]\]. Although these approaches are effective at validating significant miRNAs, they do not provide information on how they regulate expression of their target mRNAs, as relevant to the pathway level.

In this work, we propose a structured component-based analysis, for integrating omics data for identifying multiple accurate biomarkers. It is well known that miRNAs affect phenotypes indirectly, by regulating mRNA expression or protein translation \[[@CR8]\]. Herein, we propose **hi**erarchical **s**tructured **com**ponent analysis of **mi**RNA-**m**RNA **i**ntegration (HisCoM-mimi) analysis, which models biological relationships as structured components, to efficiently yield integrated markers. Our proposed model is based on generalized structured component analysis (GSCA), which tests hypothesized relationships between observed and latent variables \[[@CR12]\]. GSCA is a component-based method whereby each component represents a latent variable. Extending GSCA, we previously developed Pathway-based approach using hierarchical components of collapsed rare variants (PHARAOH) \[[@CR13]\]. PHARAOH uses a hierarchial structure of rare variants, genes, and pathways. The advantage of such hierarchical structural component models is their generation of (unobservable) latent variables, such as genes and pathways, which are inferred by observed variables, such as rare variants. Using latent variables, we can collapse unstructured data into a structured form, providing less ambiguous biological explanations of the results. In this current work, mRNAs, inhibited by miRNAs, can be merged into latent variables.

Accordingly, our proposed HisCoM-mimi model can efficiently account for biological relationships between miRNA and mRNA, in the structured component, and effectively provide integrated (e.g., miRNA-to-target-mRNA) markers. As an illustration, we tried HisCoM-mimi for identifying biomarkers for the early diagnosis of pancreatic cancer (PC). Note that PC is one of the most fatal diseases in the world, having a mere 8% five-year survival rate in the USA and a 9.4% survival rate in the Republic of Korea \[[@CR14]--[@CR16]\]. In particular, the tumor heterogeneity in PC patients' tumors makes early diagnosis harder than cancers of most other organs \[[@CR17]\]. To adjust for heterogeneity among tumor cells, we need a more robust and complex statistical model which can interpret and integrate several causes of cancer altogether. Although many bioinformatics research studies have been performed to find diagnostic markers for PC, to date, no clinically approved prognostic markers exist \[[@CR18]\].

Here, we applied HisCoM-mimi to computationally identify diagnostic markers of pancreatic ductal adenocarcinoma (PDAC), the most common type of PC. By applying the HisCoM-mimi approach to miRNA and mRNA microarray data from PDAC patients, at Seoul National University Hospital (SNUH), we identified numerous cognate miRNA-mRNA partners, as markers for diagnosis of PDAC. Finally, our HisCoM-mimi provided integrated marker sets, with more biological and intuitive interpretation, than other existing methods.

Methods {#Sec2}
=======

Pancreatic ductal adenocarcinoma (PDAC) samples {#Sec3}
-----------------------------------------------

Between the years 2009 and 2012, 200 pancreatic ductal adenocarcinoma (PDAC) samples were collected by the Department of Hepatobiliary and Pancreas Surgery of Seoul National University Hospital. The study protocol was approved by the Institutional Review Board of Seoul National University Hospital (IRB H-0901-010-267) and written, informed consent was obtained from each patient or legally authorized representative.

Of the 200 tumors, 96 were excluded because of RNA degradation or insufficient RNA content, leaving 104 samples valid for microarray analysis. After quality control, 97 PDAC samples remained for microarray assessment. The PDAC patients' average age was 64.3 years (standard deviation (SD): 9.7). Twenty-nine patients were male, and 31 female. For the normal groups, 17 benign pancreatic tissues were used. Subsequently, we built and implemented our mini model, using the 97 PDAC and 17 normal tissues, respectively.

HisCoM-mimi model {#Sec4}
-----------------

To perform the integration analysis of miRNA and mRNA data, we developed and implemented our HisCoM-mimi approach. This model analyzes multiple subnetworks simultaneously, with specific regard to inverse correlations between mRNA and miRNA. Figure [1](#Fig1){ref-type="fig"} shows the flowchart of the method. First, for a given miRNA, a miRNA-mRNA subnetwork, consisting of one miRNA and multiple potential target mRNAs, is constructed if the following two conditions are satisfied: (i) the mRNAs are reported as target of the miRNA by TargetScan 7.1 ([targetscan.org](http://targetscan.org)) \[[@CR19]\], and the negative correlation coefficients between the mRNA and miRNAs are significant (*p*-value \< 0.05). Second, for all entities deemed significant, we derived our hierarchical structural component model by using all miRNA-mRNA subnetworks.Fig. 1Flow chart for analyzing mRNA-miRNA integration

As shown in Fig. [2](#Fig2){ref-type="fig"}, there are three structures to consider: miRNA-mRNA structure, miRNA integration latent structure, and phenotype-latent structure. Each structure can be represented as a generalized linear model, similar to PHARAOH \[[@CR13]\].Fig. 2Network Diagram for HisCoM-mimi model

### miRNA-mRNA structure {#Sec5}
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Equation (1) shows how to obtain mRNA expression before inhibition by miRNA, subscript *i* means *i* th individual, *x*~*ijk*~ represents the mRNA expression of the *k*th gene related with *j* th miRNA, *z*~*j*~ the *j* th miRNA expression, *γ*~*jk*~ the inhibition coefficient for the *j* th miRNA for the *k* th gene, and *G*~*j*~ is the number of inhibited mRNAs by the *j* th miRNA. By estimating the coefficients *γ*~*jk*~, mRNA expression after removing the inhibition effect of miRNA can be obtained.

### miRNA latent structure {#Sec6}
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The miRNA latent variable is defined in Eq. (2). The miRNA latent variable is built by linearly combining miRNA expression values. While *γ*~*j*0~ denotes the direct effect of the miRNA on the phenotype. Then, the latent variable *f*~*ij*~ represents the global effect of the miRNA's activity through its inhibited mRNAs.

### Phenotype-latent structure {#Sec7}
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Let the phenotype variable *y*~*i*~ be a binary variable, distinguishing PDAC from normal tissues. Let *π*~*i*~ be the probability of *y*~*i*~ = 1 (PDAC). *logit*(*π*~*i*~) is the logit link function, *β*~*j*~ represents the effect of *f*~*ij*~ on the phenotype, as interpreted as a log-odds ratio.

### Fitting the HisCoM-mimi algorithm {#Sec8}

To estimate the parameters for HisCoM-mimi, we adopted our previously developed PHARAOH algorithm \[[@CR13]\], which is based on the alternating least squares algorithm for the penalized log-likelihood function, with ridge parameters. Then, the objective function to maximize is given as follows:$$\documentclass[12pt]{minimal}
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To maximize the objective function, *φ*~1~, the iterative reweighted least squares (IRWLS) algorithm is used. Note that when using IRWLS, maximizing *φ*~1~ is equivalent to minimizing the object function *φ*~2~.$$\documentclass[12pt]{minimal}
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Comparative models {#Sec9}
------------------

To compare the results of HisCoM-mimi with other methods, we considered several alternative regression-based methods.$$\documentclass[12pt]{minimal}
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Firstly, we considered the ordinary penalized logistic regression (LR) methods such as lasso or elastic-net (EN) \[[@CR20], [@CR21]\]. Equation 7 shows the LR model, where *θ*~*j*~ and *ρ*~*k*~ represent the effect of the *j*th miRNA and the *k*th mRNA, respectively. Equation 8 is the objective function to maximize for finding optimal parameters with the penalty function *P*~*α*~(*θ*, *ρ*). When lasso is used, *P*~*α*~(*θ*, *ρ*) =∑~k~ ∣ *ρ*~*k*~ ∣  + ∑~j~ ∣ *θ*~*j*~∣.
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Secondly, we considered LR with a group lasso penalty (GL) \[[@CR22]\], which has the benefit of using group information among the miRNAs and mRNAs of interest. In our analysis, a group can be defined as a set of one miRNA and its corresponding inhibited target mRNAs. GL uses the same LR in (8) with a different penalty function $\documentclass[12pt]{minimal}
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                \begin{document}$$ P\left(\theta, \rho \right)={\sum}_{j=1}^J\sqrt{\theta_j^2+{\sum}_{k=1}^{G_j}\left|{\rho}_k\right|} $$\end{document}$. Via this penalty function, miRNA integration set can be selected together. However, the GL approach does not easily provide *p*-values for each set of independent variables.

To fit the penalized LR models, we first performed 3-fold cross-validation to find the optimal tuning parameter, δ. after which we fitted the models with all the data sets.

Simulation study {#Sec10}
----------------

To compare HisCoM-mimi to the other three methods, we performed simulation studies and computed type I errors and power, simulating data from the same miRNA and mRNA data structure in our pancreatic cancer dataset. That is, we selected miRNA and mRNA data from the pancreatic cancer dataset, and then generated phenotype data iteratively from the LR model. We then considered two simulation scenarios. Scenario 1 assumed that a true causal integration set contains two mRNAs, with the same effect size. Scenario 2 assumed that a true causal integration set contains five mRNAs, with the same effect size. For each scenario, we randomly selected one causal miRNA-mRNA subnetwork, and then randomly selected another 9 miRNA-mRNA subnetworks, for which the number of inhibited mRNAs was less than 10. The selected miRNA-mRNA subnetworks for Scenario 1 are summarized in Table [1](#Tab1){ref-type="table"} and for Scenario 2 are in Table [2](#Tab2){ref-type="table"}.Table 1List of used miRNAs and mRNAs for simulation Scenario 1miRNARole in simulationInhibited mRNAmiR-217CausalITGBL1, ATP10AmiR-215Non-CausalCDC6, CTH, DNAJC19, DPP10, ELP4, FUNDC2, GLP1R, B3GALNT2, SLC39A8miR-485Non-CausalCDX1, CTDNEP1, GPR3, HDAC5, KCNJ11, RASL10A, SLC39A14miR-195Non-CausalCNDP2, SLC45A2, SLC7A2miR-381Non-CausalDKK3, IGFBP5, LAMA4, OSBPL3, BAMBImiR-132Non-CausalGLRB, GMPR, ARX, SALL3miR-363Non-CausalSOSTDC1miR-1Non-CausalFAM150BmiR-28Non-CausalSRPRBmiR-200Non-CausalNRG3Table 2List of used miRNAs and mRNAs for simulation Scenario 2miRNARole in simulationinhibited mRNAmiR-381CausalDKK3, IGFBP5, LAMA4, OSBPL3, BAMBImiR-215Non-CausalCDC6, CTH, DNAJC19, DPP10, ELP4, FUNDC2, GLP1, B3GALNT2, SLC39A8miR-32Non-CausalCOL1A2, BGNmiR-195Non-CausalCNDP2, SLC45A2, SLC7A2miR-501Non-CausalPARM1, SLC32A1miR-1Non-CausalFAM150BmiR-212Non-CausalKCNK2miR-204Non-CausalCDH11miR-200Non-CausalNRG3miR-363Non-CausalSOSTDC1

For Scenario 1, we used miR-217 as a true causal miRNA. To generate phenotypes, we considered the following LR model.$$\documentclass[12pt]{minimal}
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For Scenario 2, we assumed that a true causal integration set contains five mRNAs, with the same effect size. In our dataset, miR-381 was the only miRNA having five inhibited target mRNAs. To generate phenotypes, we considered the following LR model:$$\documentclass[12pt]{minimal}
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Results {#Sec11}
=======

Simulation results {#Sec12}
------------------

For our analyses, we first determined the false positive error rates (FPRs) of each method, and chose the threshold values of T to make each penalized method provide (hold) FPRs close to 0.05. In Scenario 1, the type I error rate of HisCoM-mimi was 0.048 when α = 0.05. The FPRs of lasso were 0.054, when T was 1, and that of EN was 0.064, when T was 1. Since type I error rates of lasso and EN were nearly 0.05 when T = 1, we set T = 1 to evaluate power of those two methods. The FPR of GL, when choosing a causal miRNA integration set, 0.064.

For Scenario 2, Table [3](#Tab3){ref-type="table"} shows the FPRs for lasso and EN, when varying the threshold T. For this result, we found that the type I error of lasso and EN were similar to 0.05, when T = 1 and 2, respectively. The type I error rate of HisCoM-mimi was 0.054. On the other hand, GL did not select a causal miRNA integration set at all, such that the type I error rate was 0. Secondly, we compared the powers of each method for Scenarios 1 and 2. Figure [3](#Fig3){ref-type="fig"} shows bar plots of powers for scenario 1, where the x-axis shows the effect sizes (i.e., beta coefficients), and the y-axis shows the power. HisCoM-mimi showed the highest power, while EN was second, Lasso was third, and GL was last. The same tendency is shown in Fig. [4](#Fig4){ref-type="fig"}, for Scenario 2. Figure [5](#Fig5){ref-type="fig"} shows that the differences of power between HisCoM-mimi and the others were much larger than those of Scenario 1. Consequently, GL could not find any significant miRNA-mRNA integration sets under Scenario 1, due to its GL's penalty being too strict for many mRNAs, whose beta values were small.Table 3False positive rate when varying the number of selected mRNAs for lasso and ENT54321Lasso000.0070.0220.053EN00.0020.0140.0550.204Fig. 3Power comparison for scenario 1Fig. 4Power comparison for scenario 2Fig. 5Venn Diagram for number of detected miRNAs for each method

Constructing miRNA-mRNA subnetworks {#Sec13}
-----------------------------------

To use human mRNA and miRNA probes, we first filtered out non-annotated mRNA probes and non-human miRNA probes. After filtering, there were 22,077 mRNA probes and 3391 miRNA probes. To construct miRNA-mRNA subnetworks, we checked predicted target mRNAs, for each miRNA, from TargetScan 7.1 ([targetscan.org](http://targetscan.org)) \[[@CR19], [@CR23]\]. Among predicted targets, we only selected mRNAs having significant Pearson correlation coefficients with a specific miRNA. After filtering, there were 55 miRNAs, and 2411 edges connected with mRNAs.

Integration analysis for the PDAC data {#Sec14}
--------------------------------------

Table [4](#Tab4){ref-type="table"} shows the top significant weights of miRNA-mRNA integrations derived from HisCoM-mimi. To perform multiple comparison, we used false discovery rate (FDR) q-values summarized in the 7th column \[[@CR24]\]. We could only find 12 miRNAs having q-values below 0.05. Tables [5](#Tab5){ref-type="table"} and [6](#Tab6){ref-type="table"} show the lists of the selected markers by lasso and EN, respectively. Since lasso and EN select markers without any group information, they selected miRNA and mRNA markers independently. There were no miRNAs selected by lasso or EN directly, with lasso yielding only two significant mRNAs, both related to miR-326. Other mRNAs were independently selected from different miRNAs. Consequently, there were only 12 markers selected by lasso. For EN, 58 mRNAs were selected. Similar to the lasso result, there were no selected miRNAs, although four miRNAs (miR-206, miR-3064, miR-222, and miR-326) connected to more than three mRNAs. Figure [5](#Fig5){ref-type="fig"} shows a Venn diagram of the number of miRNAs selected by each method. Each number represents the total number of detected miRNAs and one in the parenthesis does the number of detected miRNAs whose relationship with pancreatic cancer were reported. HisCoM-mimi selected larger number of unique miRNAs and the majority of them were already were reported.Table 4Significant miRNAs produced by HisCoM-mimiOrdermiRNANumber of inhibited mRNAsNumber of significant mRNAs***β*** ~***mimi***~*P* ~*HisCoM-mimi*~*q* ~*HisCoM-mimi*~1miR-133b81290.3190.00080.01262miR-141105570.6380.00080.01263miR-222127700.5870.00100.01264miR-5321100.1900.00100.01265miR-938036−0.5730.00140.01266miR-2192630.2780.00160.01267miR-590244−0.1830.00160.01268miR-3261300.1720.00220.01519miR-2036511−0.2610.00260.015910miR-13240−0.2040.00340.018711miR-96109420.7010.00380.019012miR-708433−0.1810.01020.0468Table 5Selected markers by lasso. Twelve markers (12 mRNAs) were selected. No miRNAs were selectedSelected markerBetaConnected miRNASelected markerBetaConnected miRNANSD1− 0.704miR-206PLCE10.129miR-1271EMX2−0.336miR-222TFCP20.112miR-497BBC30.329miR-222AKAP7−0.017miR-1297GSG10.005miR-3064MAMDC21.044miR-670ZRANB3−0.414miR-326DRGX0.393miR-96MLEC0.051miR-362FBXL2−0.187miR-133bTable 6Markers selected by ENSelected mRNABetaConnected miRNASelected mRNABetaConnected miRNASelected mRNABetaConnected miRNANSD1− 0.340miR-206NUP214−0.103miR-3064TFCP20.216miR-497FRS2−0.046miR-206TCP11−0.077miR-3064KDM5B0.040miR-524MGAT4A0.004miR-206BCL2L13−0.022miR-3064RNASEH2C−0.043miR-670SLC8A10.022miR-206SLC16A10−0.016miR-3064MAP3K100.163miR-670PI4KA0.027miR-206GSG10.034miR-3064MAMDC20.395miR-670MATR30.034miR-206LRRC34−0.159miR-326TCEB3−0.286miR-93OSBPL80.088miR-206ZRANB3−0.127miR-326RASL11B0.036miR-93EMX2−0.275miR-222AQP2−0.037miR-326KIAA00870.182miR-96KIAA0430−0.039miR-222CTRC−0.007miR-326DRGX0.249miR-96AXIN20.003miR-222MLEC0.034miR-362HS3ST20.016miR-100PRUNE0.013miR-222NOTCH10.003miR-367SYDE20.098miR-107SHISA90.016miR-222SH3PXD2A0.014miR-367AKAP7−0.207miR-1297SHC30.031miR-222PTDSS10.017miR-372FBXL2−0.373miR-133bRBL10.044miR-222CATSPER40.002miR-378CLIP20.005miR-141SOCS10.053miR-222TRIM550.071miR-378LYPD30.188miR-152SH3BP40.057miR-222SLC35E2B−0.128miR-488PAQR90.308miR-152BBC30.074miR-222SALL4−0.080miR-1271SCN1A0.017miR-203SEC23IP0.077miR-222MAGI30.009miR-1271CCPG10.070miR-211ESR10.085miR-222PLCE10.198miR-1271BGN−0.161miR-32DGKI−0.003miR-330-5p

For the lasso group only one miRNA (miR-32) and whose related two mRNA (COL1A2, and BGN) were selected. Although miR-32 is not reported as pancreatic cancer marker, there were some reports that miR-32 is related with other cancers \[[@CR25], [@CR26]\].

Table [7](#Tab7){ref-type="table"} summarizes miRNAs detected by HisCoM-mimi, lasso, EN, or GL. Previously, miR-93, miR-219, miR-141, miR-222, miR-203, miR-132, miR-96, and miR-206 were reported to be pancreatic cancer-related markers \[[@CR27]--[@CR35]\]. Although other miRNAs detected by HisCoM-mimi, lasso, EN, or GL have not been reported for pancreatic cancer relation, miR-532, miR-590, miR-133b, miR-326, miR-708, miR-3064, and miR-32 were reported to associate with other cancer types \[[@CR25], [@CR36]--[@CR42]\].Table 7Cancer related miRNAs detected by methodsMethodmiRNANumber of used mRNAReported cancer relationshipMethodmiRNANumber of used mRNAReported cancer relationshipHisCoM-mimimiR-9380PancreasHisCoM-mimimiR-1324PancreasHisCoM-mimimiR-21926PancreasHisCoM-mimimiR-96109PancreasHisCoM-mimimiR-53211OtherHisCoM-mimimiR-70843OtherHisCoM-mimimiR-59024OtherLassomiR-2222PancreasHisCoM-mimimiR-141105PancreasENmiR-2067PancreasHisCoM-mimimiR-133b81OtherENmiR-22212PancreasHisCoM-mimimiR-222127PancreasENmiR-30645OtherHisCoM-mimimiR-20365PancreasENmiR-3264OtherHisCoM-mimimiR-32613Other cancerGLmiR-322Other

Table [8](#Tab8){ref-type="table"} shows the cross-validation (CV) results for comparing prediction performance for marker-sets selected by HisCoM-mimi, Lasso, EN, and Group Lasso. The first column indicates methods used to construct prediction model and the second column does the method to select marker sets. The third column shows the area under the Receiver Operating Characteristic curve (AUC) results performed by leave-one-out cross validation (LOOCV). This setting is from the previous study of Kwon et al. \[[@CR23]\]. The fourth column indicates the average AUC values performed by four-fold CV with a hundred iterations. Here, we used four-fold and eight-fold CV to balance the number of samples in CV datasets. The fifth column indicates the average AUC values performed by eight-fold CV with a hundred iterations. For all selected marker-sets, all prediction models built by HisCoM-mimi showed the best performances yielding AUC values higher than 0.9 except the marker-set selected by Group lasso in which the number of markers is less than five and one path coefficient exists.Table 8Evaluation of Prediction performance for marker set selected by HisCoM-mimi, Lasso, EN, or Group Lasso in PDAC samplesMarker setMethodAUC-loocvAUC-4-fold CVAUC-8-fold CVHisCoM-mimiHisCoM-mimi**0.9970.9960.997**Lasso0.9480.9470.948EN0.9750.9690.971Group Lasso0.8890.8880.895LassoHisCoM-mimi0.9760.9750.976Lasso0.9380.9280.939EN0.9700.9530.963Group Lasso0.9100.9100.918ENHisCoM-mimi0.9760.9760.976Lasso0.9390.9270.935EN0.9690.9570.965Group Lasso0.9110.9120.915

Discussion and conclusion {#Sec15}
=========================

In this paper, we proposed and developed a novel method, **hi**erarchical **s**tructured **com**ponent analysis of **mi**croRNA-**m**RNA **i**ntegration ("HisCoM-mimi"), to construct a component model to identifying significantly integrated miRNA-target-mRNA cognate pairs. Since HisCoM-mimi could use subgroup information, it yelded more results, as related to phenotypes (e.g. cancer, metabolic syndrome, and etc.), than those of other existing methods that lack network information.

In simulation studies, we compared the performances of HisCoM-mimi, lasso, EN, and GL. From that comparison, HisCoM-mimi showed better performance than the other three methods. Controlling type I error, by HisCoM-mimi, was easier for controlling FPRs than other methods, because HisCoM-mimi uses permutation based *p*-values. In particular, HisCoM-mimi could identify miRNA-mRNA integration sets in a much more flexible way, due to better use of a standard multiple testing framework, as compared to the other methods. In real data analysis, HisCoM-mimi succesfully identified more miRNA-mRNA integration sets for pancreatic ductal adenocarcinoma (PDAC) diagnosis, compared to the other methods. Among 12 miRNAs, whose q-values were below 0.05 by HisCoM-mimi, 7 miRNAs were previously reported to associate with a panreatic cancer \[[@CR27]--[@CR35]\]. EN found two miRNAs (miR-222, and miR-206) \[[@CR30], [@CR34]\]**.** Among two miRNAs selected by lasso, only miR-222 was reported to associate with pancreatic cancer.

Although HisCoM-mimi worked well for the PDAC data sets, further biological verification of those results are needed. In future studies, we will perform additional simulation analyses to evaluate the performance of HisCoM-mimi, under numerous conditions. Furthermore, HisCoM-mimi can be extended in many ways, for other types of phenotypes, such as time to event. Second, it can be easily applied to other cancer studies to identify miRNA-mRNA integration sets for early diagnosis and prognosis. Third, it can be extended to combine other types of omics data such as genomics, epignomics, and proteomics data. It is now established that dysregulated miRNAs play substantial roles in a myriad of diseases \[[@CR43]\]. We firmly believe that these methods for miRNA identification and their target transcripts could yield effective biomarkers and therapeutic targets, in addition to providing better understanding of disease mechanisms and etiology.
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